Max Klement


Phone: +31 (0) 35 699 30 00


Max Klement is a Principal at BGV having joined the company in 2019.

Max has prior experience in startups and in larger biotech organizations. At JHL Biotech, a biosimilars and contract manufacturing company, he led the Process Development Team and was a Project Manager for novel and biosimilar biologics. Prior to JHL Biotech, Max was a founding team member at Hummingbird Bioscience where he was a Project Manager for Pharmaceutical and Academic collaborations in gastric and liver cancer. Max holds a Ph.D. from the National University of Singapore as an A*STAR fellow where he worked in the lab of Prof. Miranda Yap on antibody engineering approaches, which culminated in a commercial out-licensing agreement. Max completed his MBA from INSEAD in 2018.

Max was part of the deal team for a number of the BGV IV investments including dualyx, VectorY, Fibrocor, and most notably, the company creation of Complement Therapeutics.



MSc Chemical and Biomolecular Engineering
PhD Chemical and Biomolecular Engineering


Hummingbird Bioscience
JHL Biotech